IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers

Background : Ten to fourteen percent of Ewing sarcoma (ES) study participants treated nationwide with IGF-1 receptor (IGF-1R)-targeted antibodies achieved tumor regression. Despite this success, low response rates and short response durations (approximately 7-weeks) have slowed the development of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Hesham M., Morani, Ajaykumar C., Daw, Najat C., Lamhamedi-Cherradi, Salah-Eddine, Subbiah, Vivek, Menegaz, Brian A., Vishwamitra, Deeksha, Eskandari, Ghazaleh, George, Bhawana, Benjamin, Robert S., Patel, Shreyaskumar, Song, Juhee, Lazar, Alexander J., Wang, Wei-Lien, Kurzrock, Razelle, Pappo, Alberto, Anderson, Peter M., Schwartz, Gary K., Araujo, Dejka, Cuglievan, Branko, Ratan, Ravin, McCall, David, Mohiuddin, Sana, Livingston, John A., Molina, Eric R., Naing, Aung, Ludwig, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408058/
https://www.ncbi.nlm.nih.gov/pubmed/32630797
http://dx.doi.org/10.3390/cancers12071768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408058/
https://www.ncbi.nlm.nih.gov/pubmed/32630797
http://dx.doi.org/10.3390/cancers12071768

Ejemplares similares